BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.9 USD | +2.21% |
|
+3.27% | -13.07% |
| May. 31 | Biogen: Brussels grants marketing authorization for Charcot disease | CF |
| May. 31 | Disaster averted |  |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 53,543 | 37,679 | 35,242 | 39,877 | 37,495 | 32,751 | - | - |
| Enterprise Value (EV) 1 | 51,733 | 41,723 | 37,820 | 40,560 | 43,384 | 35,745 | 33,364 | 29,750 |
| P/E ratio | 9.44 x | 9.87 x | 23.1 x | 13.3 x | 32.5 x | 17.4 x | 14.9 x | 12.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.72 x | 2.8 x | 3.21 x | 3.92 x | 3.81 x | 3.44 x | 3.43 x | 3.31 x |
| EV / Revenue | 3.6 x | 3.1 x | 3.44 x | 3.99 x | 4.41 x | 3.75 x | 3.49 x | 3.01 x |
| EV / EBITDA | 6.41 x | 5.56 x | 9.13 x | 11.2 x | 14.3 x | 10.7 x | 9.28 x | 7.42 x |
| EV / FCF | 7.88 x | 11 x | 11.2 x | 35.5 x | 34.2 x | 15.8 x | 11.9 x | 10.2 x |
| FCF Yield | 12.7% | 9.12% | 8.94% | 2.82% | 2.93% | 6.34% | 8.37% | 9.77% |
| Price to Book | 3.87 x | 3.7 x | 3.26 x | 3.02 x | 2.53 x | 1.93 x | 1.7 x | 1.49 x |
| Nbr of stocks (in thousands) | 180,442 | 153,882 | 146,893 | 144,001 | 144,898 | 145,597 | - | - |
| Reference price 2 | 296.7 | 244.9 | 239.9 | 276.9 | 258.8 | 224.9 | 224.9 | 224.9 |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14,378 | 13,445 | 10,982 | 10,173 | 9,836 | 9,520 | 9,561 | 9,892 |
| EBITDA 1 | 8,070 | 7,504 | 4,144 | 3,618 | 3,040 | 3,333 | 3,594 | 4,008 |
| EBIT 1 | 7,390 | 6,837 | 3,656 | 3,099 | 2,545 | 2,873 | 3,077 | 3,357 |
| Operating Margin | 51.4% | 50.85% | 33.3% | 30.47% | 25.87% | 30.18% | 32.19% | 33.93% |
| Earnings before Tax (EBT) 1 | 7,126 | 5,048 | 1,745 | 3,592 | 1,297 | 2,306 | 2,810 | 3,368 |
| Net income 1 | 5,888 | 4,001 | 1,556 | 3,047 | 1,161 | 1,925 | 2,235 | 2,654 |
| Net margin | 40.96% | 29.76% | 14.17% | 29.95% | 11.8% | 20.22% | 23.38% | 26.83% |
| EPS 2 | 31.42 | 24.80 | 10.40 | 20.87 | 7.970 | 12.96 | 15.09 | 18.35 |
| Free Cash Flow 1 | 6,564 | 3,805 | 3,382 | 1,144 | 1,270 | 2,267 | 2,794 | 2,906 |
| FCF margin | 45.65% | 28.3% | 30.8% | 11.25% | 12.91% | 23.82% | 29.22% | 29.37% |
| FCF Conversion (EBITDA) | 81.34% | 50.71% | 81.61% | 31.62% | 41.79% | 68.03% | 77.73% | 72.5% |
| FCF Conversion (Net income) | 111.47% | 95.11% | 217.34% | 37.55% | 109.4% | 117.81% | 124.98% | 109.48% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,734 | 2,532 | 2,589 | 2,508 | 2,544 | 2,463 | 2,456 | 2,530 | 2,386 | 2,290 | 2,384 | 2,408 | 2,450 | 2,380 | 2,412 |
| EBITDA 1 | 780.7 | 844.1 | 1,112 | 991 | 792.7 | 674.7 | 797.7 | 853.1 | 697.5 | 795.5 | 964.8 | 990.3 | 1,033 | - | - |
| EBIT 1 | 646 | 708.6 | 976.7 | 870 | 672.9 | 467.5 | 674.2 | 728.1 | 557.4 | 648 | 721.7 | 734.7 | 728.4 | 719.3 | 755.9 |
| Operating Margin | 23.63% | 27.99% | 37.72% | 34.68% | 26.45% | 18.98% | 27.45% | 28.78% | 23.36% | 28.29% | 30.27% | 30.52% | 29.73% | 30.23% | 31.34% |
| Earnings before Tax (EBT) 1 | 405 | 347.4 | 1,270 | 1,371 | 603.8 | 438.3 | 708.1 | -141.2 | 291.6 | 464.8 | 627.3 | 545 | 549.5 | 512.5 | 526.5 |
| Net income 1 | 368.2 | 303.8 | 1,058 | 1,135 | 550.4 | 387.9 | 591.6 | -68.1 | 249.7 | 393.4 | 525.9 | 481.4 | 490.1 | 458 | 488.3 |
| Net margin | 13.47% | 12% | 40.86% | 45.23% | 21.64% | 15.75% | 24.09% | -2.69% | 10.47% | 17.18% | 22.06% | 19.99% | 20% | 19.25% | 20.24% |
| EPS 2 | 2.500 | 2.060 | 7.240 | 7.840 | 3.790 | 2.670 | 4.070 | -0.4700 | 1.710 | 2.700 | 3.599 | 3.184 | 3.361 | 3.290 | 3.405 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/3/22 | 5/3/22 | 7/20/22 | 10/25/22 | 2/15/23 | 4/25/23 | 7/25/23 | 11/8/23 | 2/13/24 | 4/24/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4,044 | 2,578 | 683 | 5,888 | 2,995 | 614 | - |
| Net Cash position 1 | 1,810 | - | - | - | - | - | - | 3,000 |
| Leverage (Debt/EBITDA) | - | 0.5389 x | 0.6221 x | 0.1888 x | 1.937 x | 0.8986 x | 0.1707 x | - |
| Free Cash Flow 1 | 6,564 | 3,805 | 3,382 | 1,144 | 1,270 | 2,267 | 2,794 | 2,906 |
| ROE (net income / shareholders' equity) | 47.7% | 45.2% | 26.6% | 21.2% | 15.2% | 14.3% | 14.6% | 14.5% |
| ROA (Net income/ Total Assets) | 24% | 15.4% | 11.9% | 12.6% | 4.52% | 7.56% | 7.57% | 7.86% |
| Assets 1 | 24,583 | 25,927 | 13,124 | 24,216 | 25,699 | 25,445 | 29,512 | 33,771 |
| Book Value Per Share 2 | 76.60 | 66.20 | 73.50 | 91.70 | 102.0 | 117.0 | 132.0 | 151.0 |
| Cash Flow per Share 2 | 38.00 | 26.20 | 24.30 | 9.480 | 10.60 | 19.70 | 20.10 | 24.40 |
| Capex 1 | 515 | 425 | 258 | 240 | 277 | 297 | 286 | 295 |
| Capex / Sales | 3.58% | 3.16% | 2.35% | 2.36% | 2.82% | 3.12% | 2.99% | 2.98% |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.07% | 32.75B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -17.66% | 7.32B |
- Stock Market
- Equities
- BIIB Stock
- Financials Biogen Inc.
